Microarrays

The PEPperCHIP® Transglutaminase Microarray is based on 6 transglutaminase variants (hFXIII, hTG1, hTG2, hTG3, hTG4 and hTG6) and can be used for

  • high resolution epitope mapping of anti-transglutaminase antibodies
  • antibody specificity analysis with 6 different transglutaminase antigens
  • serum antibody screening for anti-transglutaminase antibodies
  • isotype-specific IgG and IgA profiling from serum and plasma
  • correlation of anti-transglutaminase antibody responses with pathogenesis

The standard slide format of PEPperCHIP® Transglutaminase Microarrays facilitates application with standard lab infrastructures and most microarray scanners. Additional PEPperCHIP® Accessories support the straightforward use of the state-of-the-art peptide microarray solutions to ensure optimized assay conditions and best data quality.

Read more about PEPperCHIP Epitope Mapping
Poster presentation at GRC, 2016 (Girona, Spain)

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageSuccessful ISO9001:2015 recertification
  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy